Differential effects of different forms of hydroxyapatite and hydroxyapatite/tricalcium phosphate particulates on human monocyte/macrophages in vitro.
A possible complication associated with the use of hydroxyapatite (HA) or HA/tricalcium phosphate (HA/TCP) coating on the surfaces of prosthetic devices used for dental and orthopedic implants is their potential to fragment and thus exist as wear debris. In contrast to the so-called osteoconductive properties of HA or HA/TCP coatings, in particulate form these materials may lead to an adverse pattern of cellular and tissue responses at the bone-implant interface. We have established an in vitro cell culture system to characterize the biologic and biochemical effects of various particulate materials. The present study demonstrates that the HA/TCP particles derived from different sintering temperatures exhibit differential effects on cultured human monocyte/macrophages (M/M). The HA/TCP particles dried at 110 degrees C were the most biologically active, stimulating significant release of interleukin 1 beta (IL-1 beta), IL-6, tumor necrosis factor alpha, and prostaglandin E2 (PGE2), products implicated as important mediators of inflammation in diverse pathologic conditions. Other particles, sintered at either 900 or 1200 degrees C, did not stimulate production of cytokines or PGE2. HA/TCP particles from plasma-spray coatings also failed to release proinflammatory products. These results suggest that the biochemical and crystalline structural properties of particles markedly affects their capacity to modulate M/M function. This in vitro culture system should be useful in characterizing the specific physical and chemical properties of HA or HA/TCP particulates that are responsible for stimulating proinflammatory cell responses.
Harada
Y
Y
Department of Medicine and Orthopaedic Surgery, Harvard Medical School, Boston, Massachusetts 02114, USA.
Wang
J T
JT
Doppalapudi
V A
VA
Willis
A A
AA
Jasty
M
M
Harris
W H
WH
Nagase
M
M
Goldring
S R
SR
D001672:Biocompatible Materials; D002130:Calcium Phosphates / Q000737:chemistry / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D018360:Crystallography, X-Ray; D015232:Dinoprostone / Q000378:metabolism; D017886:Durapatite / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D008264:Macrophages / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D008855:Microscopy, Electron, Scanning; D009000:Monocytes / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D019736:Prostheses and Implants
D001672:Biocompatible Materials; D002130:Calcium Phosphates; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; C485838:calcium phosphate, monobasic, anhydrous; D017886:Durapatite; C020243:calcium phosphate; D015232:Dinoprostone; C485829:calcium phosphate, dibasic, anhydrous